2020
Adjunctive Antithrombotic Therapy for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement
Saito Y, Nazif T, Baumbach A, Tchétché D, Latib A, Kaple R, Forrest J, Prendergast B, Lansky A. Adjunctive Antithrombotic Therapy for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. JAMA Cardiology 2020, 5: 92-101. PMID: 31721980, DOI: 10.1001/jamacardio.2019.4367.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementAdjunctive antithrombotic therapyDual antiplatelet therapyAntithrombotic therapyAntiplatelet therapyValve replacementAortic stenosisAortic stenosis (AS) undergoing transcatheter aortic valve replacementSevere symptomatic aortic stenosisSurgical aortic valve replacementGuideline-recommended regimenOral anticoagulant useSevere aortic stenosisSingle antiplatelet therapySymptomatic aortic stenosisPatient risk factorsOngoing clinical trialsRisk prediction modelMajor bleedingOral anticoagulationAnticoagulant useStroke riskTAVR proceduresThrombotic risk
2019
Evaluation of anticoagulant and antiplatelet therapy after iliocaval stenting: Factors associated with stent occlusion
Attaran RR, Ozdemir D, Lin IH, Mena-Hurtado C, Lansky A. Evaluation of anticoagulant and antiplatelet therapy after iliocaval stenting: Factors associated with stent occlusion. Journal Of Vascular Surgery Venous And Lymphatic Disorders 2019, 7: 527-534. PMID: 31203859, DOI: 10.1016/j.jvsv.2019.01.058.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticoagulantsEndovascular ProceduresFemaleHumansIliac VeinMaleMay-Thurner SyndromeMiddle AgedPlatelet Aggregation InhibitorsPostthrombotic SyndromeProsthesis DesignRecurrenceRetrospective StudiesStentsTime FactorsTreatment OutcomeVascular PatencyVena Cava, InferiorVenous ThrombosisConceptsAcute deep vein thrombosisPost-thrombotic syndromeDeep vein thrombosisMay-Thurner syndromeDuration of anticoagulationAntiplatelet therapyPatency ratesIliocaval stentingIpsilateral deep vein thrombosisIliocaval venous stentingPrimary patency rateStent patency ratesCommon femoral veinVariety of indicationsLarge teaching hospitalVein thrombosisVenous stentingRetrospective reviewDVT groupStent groupFemoral veinProcedural dataStent patencyStent occlusionTeaching hospital
2017
Will PIONEER AF-PCI change my practice?
Ukena C, Leonardi S, Palmerini T, Lansky A, Montalescot G, Valgimigli M. Will PIONEER AF-PCI change my practice? EuroIntervention 2017, 13: e609-e612. PMID: 28781250, DOI: 10.4244/eijv13i5a95.Peer-Reviewed Original Research
2014
Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial)
Goto K, Lansky AJ, Ng VG, Pietras C, Nargileci E, Mehran R, Parise H, Feit F, Ohman EM, White HD, Bertrand ME, Desmet W, Hamon M, Stone GW. Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). The American Journal Of Cardiology 2014, 114: 1638-1645. PMID: 25312637, DOI: 10.1016/j.amjcard.2014.09.003.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAnticoagulantsCoronary AngiographyCoronary Artery DiseaseFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial RevascularizationOdds RatioPeptide FragmentsPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPrognosisRecombinant ProteinsSeverity of Illness IndexTreatment OutcomeConceptsPercutaneous coronary interventionAcute coronary syndromeType C lesionsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsC lesionsLesion complexityBivalirudin monotherapyComposite ischemiaCoronary syndromeCoronary interventionIschemic eventsMyocardial infarctionCardiology/American Heart Association classificationAdverse short-term prognosisAmerican Heart Association classificationAdverse ischemic eventsComposite ischemic eventsContemporary interventional therapyMajor bleeding complicationsMajor hemorrhagic complicationsShort-term prognosisAcute CatheterizationAntithrombotic regimensMajor bleedingSex‐based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: Three year results from the HORIZONS‐AMI trial
Yu J, Mehran R, Grinfeld L, Xu K, Nikolsky E, Brodie BR, Witzenbichler B, Kornowski R, Dangas GD, Lansky AJ, Stone GW. Sex‐based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: Three year results from the HORIZONS‐AMI trial. Catheterization And Cardiovascular Interventions 2014, 85: 359-368. PMID: 25115966, DOI: 10.1002/ccd.25630.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsChi-Square DistributionFemaleHealth Status DisparitiesHemorrhageHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionOdds RatioPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsProportional Hazards ModelsProspective StudiesRisk FactorsSex FactorsStentsTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsPrimary percutaneous coronary interventionMajor bleedingFemale sexRisk of MACEST-segment elevation myocardial infarction (STEMI) managementGlycoprotein IIb/IIIa inhibitorsAcute Myocardial Infarction trialIIb/IIIa inhibitorsHr of onsetAdverse cardiac eventsMyocardial Infarction trialHigh-risk subsetPresence of comorbiditiesMyocardial infarction managementPercutaneous coronary interventionBare metal stentsSex-based disparitiesFurther dedicated studiesLong-term managementHarmonizing OutcomesCardiac eventsCoronary interventionIschemic eventsSymptom onset
2013
Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: A systematic review and meta-analysis of randomized trials
Obonska K, Navarese EP, Lansky A, Tarantini G, Rossini R, Kozinski M, Musumeci G, Di Pasquale G, Górny B, Szczesniak A, Kowalewski M, Gurbel PA, Kubica J. Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: A systematic review and meta-analysis of randomized trials. Atherosclerosis 2013, 229: 482-488. PMID: 23672879, DOI: 10.1016/j.atherosclerosis.2013.04.022.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeRecent acute coronary syndromeOral factor Xa inhibitorsMajor bleeding complicationsNew oral anticoagulantsFactor Xa inhibitorsBleeding complicationsMajor bleedingCoronary syndromeOral anticoagulantsStandard therapyMyocardial infarctionOdds ratioXa inhibitorsSetting of ACSSystematic reviewAnti-Xa groupIntracranial bleeding ratesRecurrent MI ratesSecondary efficacy endpointsNew myocardial infarctionFactor X inhibitorsDose-related increaseEfficacy endpointPrimary endpoint
2012
Operator Versus Core Laboratory Assessment of Angiographic Reperfusion Markers in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction
Brener SJ, Cristea E, Lansky AJ, Fahy M, Mehran R, Stone GW. Operator Versus Core Laboratory Assessment of Angiographic Reperfusion Markers in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction. Circulation Cardiovascular Interventions 2012, 5: 563-569. PMID: 22828707, DOI: 10.1161/circinterventions.112.969022.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsAntithrombinsCoronary AngiographyCoronary CirculationDrug-Eluting StentsElectrocardiographyFemaleHeparinHirudinsHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionObserver VariationPaclitaxelPeptide FragmentsPercutaneous Coronary InterventionPredictive Value of TestsPrognosisRecombinant ProteinsTubulin ModulatorsConceptsPrimary percutaneous coronary interventionMyocardial blush gradeST-segment elevation myocardial infarctionPercutaneous coronary interventionTIMI flowMyocardial infarctionCoronary interventionMBG 2Post-PCI myocardial blush gradePost-PCI TIMI 3 flowPrimary PCIFinal myocardial blush gradeFinal TIMI flow 0Pre-PCI TIMI flowCore laboratory assessmentFinal TIMI flowRelative prognostic utilityTIMI flow 0Myocardial infarction (TIMI) flowTIMI 3 flowElevation myocardial infarctionImportant prognostic indicatorHarmonizing OutcomesMBG 0Reperfusion marker
2011
Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G, Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC, Lansky AJ, Nikolsky E, Dangas GD, Mehran R. Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2011, 4: 1011-1019. PMID: 21939942, DOI: 10.1016/j.jcin.2011.06.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsChi-Square DistributionChronic DiseaseDrug-Eluting StentsEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansIsraelKaplan-Meier EstimateKidney DiseasesMaleMetalsMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsProspective StudiesProsthesis DesignRecombinant ProteinsRecurrenceRisk AssessmentRisk FactorsStentsStrokeThrombosisTime FactorsTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionNet adverse cardiac eventsChronic kidney diseasePercutaneous coronary interventionTarget vessel revascularizationBare metal stentsDrug-eluting stentsHORIZONS-AMI trialElevation myocardial infarctionMajor bleedingBivalirudin monotherapyCoronary interventionKidney diseaseMyocardial infarctionRate of TVRIschemia-driven target vessel revascularizationNon-coronary artery bypassIIb/IIIa inhibitorsBenefit of bivalirudinDifferent antithrombotic strategiesAdverse cardiac eventsComposite of deathHigh rateResponse to Letters Regarding Article, “Predictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Substudy”
Lansky A, Goto K, Fahy M, Cristea E, Mehran R, Stone GW, Feit F, Ohman EM, Alexander KP, White HD, Bertrand ME, Desmet W, Hamon M. Response to Letters Regarding Article, “Predictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Substudy”. Circulation 2011, 123: e410-e411. PMID: 21648119, DOI: 10.1161/circulationaha.110.010306.Peer-Reviewed Original ResearchFrequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction
Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AJ, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möeckel M, Stone GW. Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction. Circulation 2011, 123: 1745-1756. PMID: 21482968, DOI: 10.1161/circulationaha.110.981688.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsClopidogrelCoronary RestenosisCoronary ThrombosisDrug Therapy, CombinationDrug-Eluting StentsFemaleHeparinHirudinsHumansMaleMetalsMiddle AgedMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Aggregation InhibitorsPredictive Value of TestsRecombinant ProteinsRisk FactorsTiclopidineTreatment OutcomeTubulin ModulatorsConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionElevation myocardial infarctionPercutaneous coronary interventionBare metal stentsDrug-eluting stentsStent thrombosisCoronary interventionMyocardial infarctionMetal stentsBivalirudin monotherapyOnly bare-metal stentsAcute Myocardial Infarction trialIIb/IIIa inhibitorsClopidogrel loading dosePotent antiplatelet therapyProbable stent thrombosisAcute stent thrombosisMyocardial Infarction trialAcute myocardial infarctionAntithrombin therapyHarmonizing OutcomesAntiplatelet therapyIndependent predictors
2010
When Is Door-to-Balloon Time Critical? Analysis From the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trials
Brodie BR, Gersh BJ, Stuckey T, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Grines CL, Cox D, Parise H, Prasad A, Lansky AJ, Mehran R, Stone GW. When Is Door-to-Balloon Time Critical? Analysis From the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trials. Journal Of The American College Of Cardiology 2010, 56: 407-413. PMID: 20650362, DOI: 10.1016/j.jacc.2010.04.020.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionLower mortality rateHigh-risk patientsPercutaneous coronary interventionMortality rateEarly presentationCoronary interventionClinical riskST-segment elevation myocardial infarctionSimilar relative risk reductionsHORIZONS-AMI trialElevation myocardial infarctionRelative risk reductionNon-percutaneous coronary intervention hospitalsMortality rate reductionImpact of doorCADILLAC trialHORIZONS-AMIAntithrombotic therapyReperfusion therapyBalloon timeIntervention hospitalsAbsolute benefitLate presentationMyocardial infarctionPredictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage
Goto K, Lansky AJ, Fahy M, Cristea E, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Mehran R, Stone GW. Predictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage. Circulation 2010, 121: 853-862. PMID: 20142447, DOI: 10.1161/circulationaha.109.877944.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeAcute coronary syndrome patientsCoronary syndrome patientsComposite ischemiaCoronary syndromeAngiographic screeningCoronary ectasiaIschemic outcomesJeopardy scoreSyndrome patientsUrgent Intervention Triage Strategy (ACUITY) trialGlycoprotein IIb/IIIa inhibitorsAcute coronary syndrome populationPrevious percutaneous coronary interventionIIb/IIIa inhibitorsComposite ischemic eventsEarly invasive approachAdverse cardiac eventsOutcomes of patientsPercutaneous coronary interventionPredictors of outcomeTraditional clinical parametersAcute CatheterizationBivalirudin therapyMajor bleeding
2009
Outcomes of Patients with Coronary Artery Perforation Complicating Percutaneous Coronary Intervention and Correlations with the Type of Adjunctive Antithrombotic Therapy: Pooled Analysis from REPLACE‐2, ACUITY, and HORIZONS‐AMI Trials
DOLL JA, NIKOLSKY E, STONE GW, MEHRAN R, LINCOFF AM, CAIXETA A, MCLAURIN B, CRISTEA E, FAHY M, KESANAKURTHY V, LANSKY AJ. Outcomes of Patients with Coronary Artery Perforation Complicating Percutaneous Coronary Intervention and Correlations with the Type of Adjunctive Antithrombotic Therapy: Pooled Analysis from REPLACE‐2, ACUITY, and HORIZONS‐AMI Trials. Journal Of Interventional Cardiology 2009, 22: 453-459. PMID: 19702677, DOI: 10.1111/j.1540-8183.2009.00494.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsChemotherapy, AdjuvantCoronary VesselsDrug Therapy, CombinationFemaleFibrinolytic AgentsHeparinHirudinsHumansMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexRecombinant ProteinsSurvival RateTreatment OutcomeWounds, PenetratingConceptsPercutaneous coronary interventionGP IIb/IIIa inhibitorsIIb/IIIa inhibitorsAdjunctive antithrombotic therapyUnfractionated heparinMyocardial infarctionAntithrombotic therapyCoronary interventionPCI trialProvisional glycoprotein (GP) IIb/IIIa inhibitionGlycoprotein IIb/IIIa inhibitionIIb/IIIa inhibitionBaseline creatinine clearanceHORIZONS-AMI trialGP IIb/IIIaOutcomes of patientsOnly independent predictorCoronary artery perforationManagement of patientsTreatment of patientsIIb/IIIaLower ratesSimilar ratesBivalirudin monotherapyHORIZONS-AMIGastrointestinal Bleeding in Patients With Acute Coronary Syndromes: Incidence, Predictors, and Clinical Implications Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial
Nikolsky E, Stone GW, Kirtane AJ, Dangas GD, Lansky AJ, McLaurin B, Lincoff AM, Feit F, Moses JW, Fahy M, Manoukian SV, White HD, Ohman EM, Bertrand ME, Cox DA, Mehran R. Gastrointestinal Bleeding in Patients With Acute Coronary Syndromes: Incidence, Predictors, and Clinical Implications Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial. Journal Of The American College Of Cardiology 2009, 54: 1293-1302. PMID: 19778672, DOI: 10.1016/j.jacc.2009.07.019.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAge FactorsAgedAngioplasty, Balloon, CoronaryAnticoagulantsClopidogrelCoronary Artery BypassFemaleGastrointestinal HemorrhageHeparinHirudinsHumansIncidenceIschemiaLength of StayMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRecombinant ProteinsRisk AssessmentSex FactorsStentsThrombosisTiclopidineConceptsAcute coronary syndromeGastrointestinal bleedingACUITY trialComposite ischemiaCardiac mortalityCause mortalityCoronary syndromeHigh-risk acute coronary syndromesStudy drug administrationOpen-label usePotential hemorrhagic complicationsST-segment deviationAntiplatelet medicationsBaseline anemiaHemorrhagic complicationsIschemic complicationsIndependent predictorsClinical outcomesMultivariable analysisStent thrombosisMyocardial infarctionSerious conditionPatientsDrug AdministrationOlder ageBivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW, Investigators F. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. The Lancet 2009, 374: 1149-1159. PMID: 19717185, DOI: 10.1016/s0140-6736(09)61484-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsFemaleFollow-Up StudiesHemorrhageHeparinHirudinsHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsRecombinant ProteinsStentsSurvival RateThrombosisTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionNet adverse clinical eventsPercutaneous coronary interventionAdverse clinical eventsBivalirudin groupMajor bleedingClinical eventsControl groupMyocardial infarctionAcute ST-segment elevation myocardial infarctionIIb/IIIa inhibitorsPrimary percutaneous coronary interventionHORIZONS-AMI trialMajor haemorrhagic complicationsPrimary trial endpointRate of MACERate of NACEElevation myocardial infarctionOnset of symptomsAcute myocardial infarctionOptimum treatment strategyWithdrawal of consentThrombin inhibitor bivalirudinImportant clinical implicationsImpact of Gender and Antithrombin Strategy on Early and Late Clinical Outcomes in Patients With Non–ST-Elevation Acute Coronary Syndromes (from the ACUITY Trial)
Lansky AJ, Mehran R, Cristea E, Parise H, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Stone GW. Impact of Gender and Antithrombin Strategy on Early and Late Clinical Outcomes in Patients With Non–ST-Elevation Acute Coronary Syndromes (from the ACUITY Trial). The American Journal Of Cardiology 2009, 103: 1196-1203. PMID: 19406258, DOI: 10.1016/j.amjcard.2009.01.030.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdultAge FactorsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsCause of DeathDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationElectrocardiographyEnoxaparinFemaleFollow-Up StudiesHeparinHirudinsHumansMaleMiddle AgedPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProbabilityProportional Hazards ModelsRecombinant ProteinsReference ValuesRisk AssessmentSeverity of Illness IndexSex FactorsSurvival AnalysisTime FactorsTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsElevation acute coronary syndromePercutaneous coronary interventionAcute coronary syndromeComposite ischemiaNet clinical outcomeMajor bleedingCoronary syndromeClinical outcomesNet clinical adverse eventsIIb/IIIa inhibitorsLate clinical outcomesCoronary artery bypassClinical adverse eventsImpact of genderACUITY trialBivalirudin monotherapyAntithrombotic therapyArtery bypassNon–STAdverse eventsAntithrombotic strategiesCoronary interventionIschemiaBivalirudinEarly Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal Stents
Aoki J, Lansky AJ, Mehran R, Moses J, Bertrand ME, McLaurin BT, Cox DA, Lincoff AM, Ohman EM, White HD, Parise H, Leon MB, Stone GW. Early Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal Stents. Circulation 2009, 119: 687-698. PMID: 19171852, DOI: 10.1161/circulationaha.108.804203.Peer-Reviewed Original ResearchConceptsIIb/IIIa inhibitorsAcute coronary syndromeGlycoprotein IIb/IIIa inhibitorsEarly stent thrombosisStent thrombosisCoronary syndromeBare metal stentsDrug-eluting stentsThienopyridine administrationAngiographic resultsHigh-risk acute coronary syndromesUrgent Intervention Triage Strategy (ACUITY) trialMetal stentsHigher baseline hemoglobin levelsInsulin-requiring diabetes mellitusQuantitative coronary angiographic analysisStent minimal lumen diameterAntiplatelet drug useBaseline renal insufficiencyCoronary angiographic analysisSuboptimal angiographic resultsBaseline hemoglobin levelDefinite stent thrombosisProbable stent thrombosisHigh-risk patients
2008
Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial
White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, Cox DA, Pocock SJ, Ware JA, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Stone GW. Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial. Journal Of The American College Of Cardiology 2008, 52: 807-814. PMID: 18755342, DOI: 10.1016/j.jacc.2008.05.036.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsDrug Therapy, CombinationEnoxaparinFemaleFibrinolytic AgentsHeparinHirudinsHumansMaleMiddle AgedPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexRecombinant ProteinsRisk FactorsTime FactorsConceptsIIb/IIIa inhibitorsPercutaneous coronary interventionGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsHigh-risk ACS patientsImpact of bivalirudinUnfractionated heparinACUITY trialComposite ischemiaACS patientsCoronary interventionAcute coronary syndrome patientsEfficacy of bivalirudinLess major bleedingSimilar ischemic outcomesAcute coronary syndromeCoronary syndrome patientsBivalirudin monotherapyIschemic outcomesMajor bleedingCoronary syndromeSyndrome patientsBivalirudinPatientsEnoxaparinThe Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale
Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM, Parise H, Fahy M, Lansky AJ, Stone GW. The Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale. American Heart Journal 2008, 156: 44-56. PMID: 18585496, DOI: 10.1016/j.ahj.2008.02.008.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngioplasty, Balloon, CoronaryAnticoagulantsCombined Modality TherapyCoronary AngiographyDose-Response Relationship, DrugDrug Administration ScheduleDrug-Eluting StentsFollow-Up StudiesHeparin, Low-Molecular-WeightHirudinsHumansMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProbabilityProspective StudiesRecombinant ProteinsReference ValuesResearch DesignRisk AssessmentStentsSurvival RateThrombosisTime FactorsConceptsPrimary PCIPrimary percutaneous coronary interventionIIb/IIIa inhibitorsAcute myocardial infarctionBare metal stentsGP IIb/IIIa inhibitorsHORIZONS-AMI trialUnfractionated heparinGlycoprotein IIb/IIIa inhibitorsIdentical bare-metal stentOverall event-free survivalAcute Myocardial Infarction trialEnd pointDirect thrombin inhibitor bivalirudinRoutine useEfficacy end pointMyocardial Infarction trialTarget lesion revascularizationEvent-free survivalClinical end pointsPercutaneous coronary interventionPaclitaxel-eluting stentsNew pharmacologic agentsThrombin inhibitor bivalirudinDrug-eluting stents
2007
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial
Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW, investigators F. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. The Lancet 2007, 369: 907-919. PMID: 17368152, DOI: 10.1016/s0140-6736(07)60450-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsCombined Modality TherapyDrug Therapy, CombinationEnoxaparinFemaleHeparinHirudinsHumansMaleMiddle AgedMyocardial IschemiaPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecombinant ProteinsTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsPercutaneous coronary interventionAcute coronary syndromeNet clinical outcomeHigh-risk acute coronary syndromesUrgent Intervention Triage Strategy (ACUITY) trialCoronary interventionClinical outcomesMajor bleedingCoronary syndromeAcute CatheterizationStrategy trialDirect thrombin inhibitor bivalirudinAdverse ischemic eventsMajor haemorrhagic complicationsComparable clinical outcomesThrombin inhibitor bivalirudinHaemorrhagic complicationsIschemic eventsUnfractionated heparinSubgroup analysisProportion of individualsBivalirudinBleeding